PUMA BIOTECHNOLOGY INC (PBYI)
NASDAQ · Manufacturing · Pharmaceutical preparations
$9.96+$0.1372 (+1.40%) on the dayAs of the close; data may be delayed.
PBYI price, last 12 months
Key stats
- Previous close
- $9.82
- Open
- $9.87
- Day range
- $9.65 – $10.00
- 52-week range
- $4.58 – $10.00
- Volume
- 208.5K
- Avg volume (20 days)
- 304.8K
- Market cap
- $504.3M
Performance
1W+3.7%
1M+8.7%
3M+22.8%
6M+58.8%
YTD+67.4%
1Y+111.0%
vs S&P 500, 1Y+94.2 pts
Technicals and fundamentals
About PUMA BIOTECHNOLOGY INC
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $504.3M